^
Association details:
| Biomarker: | MSH6 mutation |
|---|---|
| Cancer: | Triple Negative Breast Cancer |
| Drug: | Lynparza (olaparib) (PARP inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
184PD - Neoadjuvant olaparib monotherapy in primary triple negative breast cancer (ID 3933)
Published date:
09/28/2019
Excerpt:
Interestingly, mutations in genes associated with DNA damage repair (ATRX, BRCA1/2, EMSY, MSH6, PARP10, PPM1D) occurred in n = 9/20 olaparib responders, but in none of the 11 non-responders (p = 0.011).
Trial ID:
